Literature DB >> 10952187

MRI in human immunodeficiency virus-associated cerebral vasculitis.

J Berkefeld1, W Enzensberger, H Lanfermann.   

Abstract

Cerebral ischaemia caused by inflammatory vasculopathies has been described as complication of human immunodeficiency virus (HIV) infection. Imaging studies have shown ischaemic lesions and changes of the vascular lumen, but did not allow demonstration of abnormalities within the vessel wall itself. Two HIV-infected men presented with symptoms of a transient ischaemic attack. Initial MRI of the first showed no infarct; in the second two small lacunar lesions were detected. In both cases, multiplanar 3-mm slice contrast-enhanced T1-weighted images showed aneurysmal dilatation, with thickening and contrast enhancement of the wall of the internal carotid and middle cerebral (MCA) arteries. These findings were interpreted as indicating cerebral vasculitis. In the first patient the vasculopathy progressed to carotid artery occlusion, and he developed an infarct in the MCA territory, but then remained neurologically stable. In the second patient varicella zoster virus (VZV) infection was the probable cause of vasculitis. The clinical deficits and vasculitic MRI changes regressed with antiviral and immunosuppressive therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10952187     DOI: 10.1007/s002340000328

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  12 in total

Review 1.  CNS Infections in Immunoincompetent Patients : Neuroradiological and Clinical Features.

Authors:  Stefan Weidauer; Marlies Wagner; Simon Jonas Enkirch; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2019-09-19       Impact factor: 3.649

2.  Qualitative Assessment and Reporting Quality of Intracranial Vessel Wall MR Imaging Studies: A Systematic Review.

Authors:  J W Song; S C Guiry; H Shou; S Wang; W R Witschey; S R Messé; S E Kasner; L A Loevner
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

3.  Aneurysmal vasculopathy in human-acquired immunodeficiency virus-infected adults: Imaging case series and review of the literature.

Authors:  Jayesh P Thawani; Nikhil R Nayak; Jared M Pisapia; Dmitriy Petrov; Bryan A Pukenas; Robert W Hurst; Michelle J Smith
Journal:  Interv Neuroradiol       Date:  2015-05-28       Impact factor: 1.610

4.  HIV/AIDS patients with HIV vasculopathy and VZV vasculitis: a case series.

Authors:  J Gutierrez; G Ortiz
Journal:  Clin Neuroradiol       Date:  2011-07-20       Impact factor: 3.649

5.  Stroke in patients with human immunodeficiency virus infection.

Authors:  Brent Tipping; Linda de Villiers; Helen Wainwright; Sally Candy; Alan Bryer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-30       Impact factor: 10.154

6.  Cerebral aneurysmal arteriopathy in an adult patient with acquired immunodeficiency syndrome.

Authors:  P O'Charoen; J R Hesselink; J F Healy
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

7.  Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis.

Authors:  Wilhelm Küker; Susanne Gaertner; Thomas Nagele; Christian Dopfer; Martin Schoning; Jens Fiehler; Peter M Rothwell; Ulrich Herrlinger
Journal:  Cerebrovasc Dis       Date:  2008-05-30       Impact factor: 2.762

8.  Perinatally HIV-infected youth presenting with acute stroke: progression/evolution of ischemic disease on neuroimaging.

Authors:  Izlem Izbudak; Majid Chalian; Nancy Hutton; Visveshwar Baskaran; Lori Jordan; George K Siberry; Philippe Gailloud; Allison L Agwu
Journal:  J Neuroradiol       Date:  2013-06-02       Impact factor: 3.447

9.  Vessel wall MR imaging of central nervous system vasculitis: a systematic review.

Authors:  Nathan Arnett; Athanasios Pavlou; Morgan P Burke; Brett L Cucchiara; Rennie L Rhee; Jae W Song
Journal:  Neuroradiology       Date:  2021-05-03       Impact factor: 2.804

Review 10.  Cerebral vasculitis: imaging signs revisited.

Authors:  Wilhelm Küker
Journal:  Neuroradiology       Date:  2007-03-08       Impact factor: 2.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.